How a longevity gene variant reprograms immunity through platelets

A BPIFB4 gene variant enriched in centenarians reduces systemic inflammation and protects against cardiovascular aging through an unexpected mechanism: platelet reprogramming. The team discovered that carriers of this longevity-associated variant significantly elevate CD47 levels on both reticulated and mature platelet surfaces, a pattern that mirrors centenarians themselves. When these modified platelets encounter lipopolysaccharide-activated monocytes, they selectively suppress proinflammatory cytokine production through a CD47-dependent mechanism that leaves NF-κB signaling largely intact. Most promisingly, recombinant BPIFB4 protein administered in vivo in mice fully replicated this effect, raising CD47 on wild-type platelets and reducing ex vivo monocyte activation, validating translational therapeutic potential. For the precision biohacker and clinician, this opens a concrete pathway: genetically mimic centenarian immunity without requiring the protective variant itself—a strategy that could systematically modulate the chronic inflammatory burden characteristic of aging.